Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
3.330
-0.100 (-2.92%)
At close: Jan 17, 2025, 4:00 PM
3.360
+0.030 (0.90%)
After-hours: Jan 17, 2025, 7:48 PM EST
Kyverna Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
96
Market Cap
143.76M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | 7.03M | 1.37M | 24.20% |
Dec 31, 2021 | 5.66M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionKYTX News
- 19 hours ago - The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Kyverna Therapeutics, Inc. - Accesswire
- 1 day ago - Kyverna Therapeutics, Inc. Is Being Sued For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm - Accesswire
- 3 days ago - Kyverna Therapeutics, Inc. Is Being Sued For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm - Accesswire
- 4 days ago - The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Kyverna Therapeutics Inc. - Accesswire
- 5 days ago - Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before February 7, 2025 to Discuss Your Rights - KYTX - PRNewsWire
- 5 days ago - SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics - PRNewsWire
- 6 days ago - The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Kyverna Therapeutics Inc - Accesswire
- 7 days ago - Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire